William Gradishar, MD, discusses factors to consider when determining the optimal treatment of patients with HER2-positive breast cancer.
William Gradishar, MD,
Advertisement
Articles by William Gradishar, MD,
William J. Gradishar, MD, discusses the expanding role of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.
William Gradishar, MD, Betsy Bramsen Professorship of Breast Oncology, Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses changes to the NCCN Breast Cancer Guidelines.
Advertisement
Latest Updated Articles
Dr. Gradishar on the Expanding Role of Trastuzumab Deruxtecan in HER2+ Breast CancerPublished: October 28th 2020 | Updated:
Dr. Gradishar on Integrating Novel Options Into the HER2+ Breast Cancer Treatment AlgorithmPublished: July 26th 2021 | Updated:
Dr. William Gradishar on Updates in NCCN Breast Cancer GuidelinesPublished: April 4th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5